151751-Najiba-Chargi

205 Systemic therapy: skeletal muscle mass and chemoradiotherapy Table 2. Patient characteristics in patients with low and normal SMM All patients Patients with low SMM Patients with normal SMM P value Characteristic n = 84 (%) n = 69 (%) Gender Men 64 (76.2) 48 (69.6) 0.37* Women 20 (23.8) 21 (30.4) Age at diagnosis (years) Mean (SD) 59.9 (6.3) 59.8 (7.3) 0.95 $ Smoking Never Former 14 (16.7) 8 (9.5) 11 (15.9) 8 (11.6) 0.92 # Active 62 (73.8) 50 (72.5) Body mass index (kg/m 2 ) Mean (SD) 22.1 (3.6) 25.6 (3.9) <0.01 $ ACE-27 score 0 1 2 62 (73.8) 21 (25.0) 1 (1.2) 53 (76.8) 16 (23.2) 0 (0) 0.60 # Renal function eGFR >70 73 (92.4) 57 (87.7) 0.40* eGFR 60-70 6 (7.6) 8 (12.3) Tumor site Oropharynx,HPV+ 16 (19.0) 25 (36.2) 0.12 # Oropharynx, HPV- or unknown 31 (36.9) 20 (29.0) Hypopharynx 30 (35.7) 20 (29.0) Larynx 7 (8.3) 4 (5.8) T stage 1 10 (11.9) 5 (7.2) 0.05 # 2 18 (21.4) 28 (40.6) 3 27 (32.1) 21 (30.4) 4 29 (34.5) 15 (21.7) N stage 0 10 (11.9) 9 (13.0) 0.09 # 1 11 (13.1) 6 (8.7) 2a 4 (4.8) 5 (7.2) 2b 29 (34.5) 37 (53.6) 2c 24 (28.6) 11 (15.9) 3 6 (7.1) 1 (1.4) AJCC stage II 2 (2.4) 2 (2.9) 0.11 # III 30 (35.7) 36 (52.2) IV 52 (61.9) 31 (44.9) CDLT No 54 (64.3) 62 (89.9) <0.01* Yes 30 (35.7) 7 (10.1) Bold p-value indicates a significant difference between groups. Cursive indicates a p value < 0.10 * Fisher’s exact test, # Pearson Chi square test, $ Independent student’s T test 11